Dr. Ugo Anieto Discovers ANIETOCIN (Antibiotic For Drug Resistant Infections)

Dr. Ugo Anieto is the inventor of Anietocin, an antibiotic used to treat antibiotic-resistant microbial infections. He was born in Onitsha in Anambra state & currently an Associate Professor in Microbiology at, the University of Texas.

Ozii Baba Anieto, his cousin, announced this on Twitter:

My cousin, Dr. Ugo Anieto discovered an antibiotic for drug resistant infections. He named it ANIETOCIN – after my family name.

Dr. Ugo is a scientist in Texas, USA

TEXAS A&M UNIVERSITY
Inventor

Dr. Ugochukwu Anieto Instructional Assistant Professor, College of Science Higher Education Center at McAllen

Research Areas and Divisions Bioenergy Antimicrobial resistance Food microbiology

Anietocin: A Novel Antibiotic to Treat Drug Resistant Infections

Overview
The rapid emergence of antibiotic resistant bacteria is occurring worldwide, endangering the efficacy of antibiotics, which have transformed medicine and saved millions of lives. The antibiotic resistance crisis has bcen attributed to the misuse of these medications, as well as the lack of new drug development efforts. This disclosed invention presents a new strain of Pseudomon. spp. bacteria that produces antimicrobial compounds effective against both Gram-positive and Gram-negative bacteria.

Technology
A previously unknown Pseudomonas strain has been identified and now named “Anieto”, after the TAMU inventor Dr. Anieto. The bacterium produces a novel antibiotic compound, named “Anietoci, and has been tested against several bacteria, both Gram positive and Grarn negative, for growth inhibition and has so far been effective against all test bacterial species. While resistance to antibiotics is a growing global concern, this antibiotic offers the promise of alleviating the substantial health and economic burden on healthcare systems and population. Dr. Anieto strongly believes that pharmaceutical companies can utilize this bacterium and maximize its effectiveness to treat prevailing bacterial infections in patients. His team is currently improving the chemical extraction process of this novel antibiotic and understanding the metabolomics of the bacterium to addre. large scale manufacturing opportunities.

Advantages • No resistance to antibiotic observed by targeted bacterial species yet • Broad.spectrum antibiotic provides potential hunts

Applications • Treatment of antibiotic resistant microbial infections • Surgical and sterile environments • Point of care antibiotic prescription.

Stage Of Development: undergoing laboratory trials on several bacterial species while showing consistent results.

Patent Status: U.S. Patent Application in Preparation.

56 Likes 1 Share